TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cantargia AB ( (SE:CANTA) ) has shared an update.
Cantargia AB has announced the appointment of its Nomination Committee ahead of the 2026 Annual General Meeting. The committee, representing 13% of Cantargia’s shares, is tasked with proposing key roles and remuneration for the AGM, which will be held on May 21, 2026. This development is part of Cantargia’s ongoing governance and strategic planning, potentially impacting its shareholder engagement and corporate structure.
The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform based on the IL1RAP protein, which is involved in various cancer forms and inflammatory diseases. Cantargia’s primary oncology program features the antibody nadunolimab (CAN04), which is being clinically studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Additionally, Cantargia is developing CAN10, an antibody targeting autoimmune and inflammatory diseases, which was recently acquired by Otsuka Pharmaceutical.
Average Trading Volume: 2,802,475
Technical Sentiment Signal: Buy
Current Market Cap: SEK783.1M
For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.